Chemical Property of Dichlorphenamide
Chemical Property:
- Appearance/Colour:white or nearly white crystalline powder
- Vapor Pressure:0.0079mmHg at 25°C
- Melting Point:239-241oC
- Refractive Index:1.596
- Boiling Point:590.5 °C at 760 mmHg
- PKA:pKa 7.4 (Uncertain);8.6 (Uncertain)
- Flash Point:310.9 °C
- PSA：137.08000
- Density:1.782 g/cm3
- LogP:3.85040
- Storage Temp.:Sealed in dry,Room Temperature
- Solubility.:Acetonitrile (Slightly), Chloroform, DMSO (Slightly), Methanol
- XLogP3:0.3
- Hydrogen Bond Donor Count:2
- Hydrogen Bond Acceptor Count:6
- Rotatable Bond Count:2
- Exact Mass:303.9146044
- Heavy Atom Count:16
- Complexity:452
- Purity/Quality:
-
99% *data from raw suppliers
Diclofenamide *data from reagent suppliers
Safty Information:
- Pictogram(s):
Xn
- Hazard Codes:Xn
- Statements:
63
- Safety Statements:
36
- MSDS Files:
-
SDS file from LookChem
Useful:
- Canonical SMILES:C1=C(C=C(C(=C1S(=O)(=O)N)Cl)Cl)S(=O)(=O)N
- Recent ClinicalTrials:Hyper- and Hypokalemic Periodic Paralysis Study
- Recent EU Clinical Trials:Double-blind, placebo-controlled, parallel group, phase III study comparing dichlorphenamide vs. placebo for the treatment of periodic paralysis
-
Uses
Diclofenamide is a potent carbonic anhydrase inhibitor. Diclofenamide may provide a therapeutic strategy in the inhibition of the human cytosolic isoforms I and II and transmembrane tumor-associated i
soenzymes IX and XII. Diclofenamide has been shown to be is effective in the prevention of episodic weakness in both hypokalemic periodic paralysis (HypoPP) and potassium-sensitive periodic paralysis
(PSPP). Like the drugs described above, dichlorphenamide is used for secreting excess water in
cases of elevated intraocular pressure, and it is used for treating wide-angle and secondary
glaucoma as well as in cases where it is necessary to lower intraocular pressure before surgical
intervention in severe wide-angle glaucoma. Diclofenamide is a potent carbonic anhydrase inhibitor. Diclofenamide may provide a therapeutic strategy in the inhibition of the human cytosolic isoforms I and II and transmembrane tumor-associated isoenzymes IX and XII. Diclofenamide has been shown to be is effective in the prevention of episodic weakness in both hypokalemic periodic paralysis (HypoPP) and potassium-sensitive periodic paralysis (PSPP).
-
Therapeutic Function
Carbonic anhydrase inhibitor, Antiglaucoma
-
Clinical Use
Dichlorphenamide is a disulfonamide derivative that
shares the same pharmacological properties。The dose of dichlorphenamide is 25 to 100 mg one to three times
a day.
